CN115708846A - Negative hydrogen material composition and preparation method thereof - Google Patents
Negative hydrogen material composition and preparation method thereof Download PDFInfo
- Publication number
- CN115708846A CN115708846A CN202211418618.0A CN202211418618A CN115708846A CN 115708846 A CN115708846 A CN 115708846A CN 202211418618 A CN202211418618 A CN 202211418618A CN 115708846 A CN115708846 A CN 115708846A
- Authority
- CN
- China
- Prior art keywords
- material composition
- extract
- hydrogen
- negative
- prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a negative hydrogen material composition and a preparation method thereof, wherein the negative hydrogen material composition is prepared from the following raw materials in parts by weight: 380-400 parts of oyster meat extract; 100-120 parts of ganoderma lucidum extract; 100-120 parts of lycium ruthenicum extract; 90-110 parts of negative hydrogen oyster calcium powder; 80-84 parts of starch; 5-9 parts of magnesium stearate. The negative hydrogen material composition has the health-care functions of resisting oxidation and inhibiting aging.
Description
Technical Field
The invention relates to the field of negative hydrogen materials, in particular to a negative hydrogen material composition and a preparation method thereof.
Background
Negative hydrogen ion "H - "is a negative ion" H with one more electron on hydrogen atom - "。
The negative hydrogen ions have four main characteristics: (1) The negative hydrogen ion is the lightest substance in nature, but is one with the strongest oxidation resistance; h in reduced nicotinamide adenine dinucleotide NADH (reduced coenzyme I) is negative hydrogen ions, oxidized coenzyme I (NAD) is formed and negative ions are released; thus, NADH is the carrier of the negative hydrogen ion. (2) The negative hydrogen ion is an important factor participating in synthesis and conversion of ATP, normally, ATP generated directly by metabolism during glucose metabolism is very little, and NADH generated by metabolism can generate a large amount of ATP through an electron transfer and an oxidation reaction of phosphate. (3) The negative hydrogen ions participate in the modification of nucleic acid by enzyme and the interaction between biomacromolecules. The negative hydrogen ion has relatively small molecules, fast cell entering speed and high reducibility as one important matter, so that the negative hydrogen ion can improve the metabolism and circulation of cell and is favorable to repair tissue and organ. (4) The negative hydrogen ion has small volume, the hydrogen atom diameter is only 0.064nm, the negative hydrogen ion has extremely light weight and can rapidly enter cells, the negative hydrogen ion can easily enter any tissue, such as liver, heart, lung, kidney, brain, skin, muscle and the like, and plays the roles of oxidation resistance and energy carrier, thereby forming a special biological environment in vivo.
Although the negative hydrogen ion has a good biochemical effect, the negative hydrogen ion cannot exist alone in nature and is difficult to prepare and store.
In 2013, the inventor invents powder carrying negative hydrogen ions and a preparation method thereof, applies and authorizes an invention patent with the patent number of ZL201310755613.1, and authorizes publication numbers of: CN103710028B, the date of authorized bulletin is 2014.12.24; the method comprises the steps of crushing shells from which organic matters are removed, roasting at high temperature to enable the obtained powder to have a nano-micro structure, and fixing negative hydrogen ions obtained in a plasma state in the nano-micro structure powder. Once the powder is mixed with water, negative hydrogen ions are released, and the characteristics of water are changed by the negative hydrogen ions, so that common water has the characteristics of negative potential, alkalescence and the like. The negative hydrogen ion-loaded powder provided by the invention has the negative hydrogen ion concentration as high as 252ppb when being released in water. However, the negative hydrogen ion-supporting powder provided by the present invention has not yet developed more functions.
Disclosure of Invention
In view of this, the present invention provides a negative hydrogen material composition and a preparation method thereof, and the prepared negative hydrogen material composition has health care functions of oxidation resistance and aging inhibition.
The adopted technical scheme is as follows:
the invention relates to a negative hydrogen material composition which is prepared from the following raw materials in parts by weight:
further, the feed additive is prepared from the following raw materials in parts by weight:
further, the oyster meat extract is prepared by the following method: grinding fresh oyster meat into slurry, decocting the slurry in pure water for 2-3 times, each time for 1-2 hr, mixing decoctions, concentrating under reduced pressure, and lyophilizing to obtain oyster meat extract.
Further, the ganoderma lucidum extract is prepared by the following method: weighing Ganoderma lucidum, pulverizing, extracting with 75% volume ethanol under reflux for 1-2 hr according to the mass ratio of the material liquid of 1-6, and centrifuging at 2000rpm for 10min to obtain supernatant as extractive solution; performing silica gel column chromatography on the extract, eluting with chloroform-methanol mixed solution with volume ratio of 4.
Further, the lycium ruthenicum extract is prepared by the following method: grinding fresh lycium ruthenicum, adding deionized water, soaking for 30 minutes, boiling for 30 minutes, and filtering; and then boiling the filtrate with water for 30min, filtering, and concentrating the secondary filtrate under reduced pressure to 2-3g/mL to obtain the lycium ruthenicum extract.
Further, the hydrogen-negative oyster calcium powder is prepared by treating oyster shell powder with particle size of 200-300 meshes at 700 deg.C under nitrogen protection; and (3) treating the treated oyster shell powder at the temperature of 1000 ℃ under the protection of mixed gas of hydrogen and nitrogen to obtain the negative hydrogen oyster calcium powder.
The preparation method of the negative hydrogen material composition is characterized by comprising the following steps:
mixing Carnis Ostreae extract, ganoderma extract, fructus Lycii extract, concha Ostreae calcium powder and starch, granulating, adding magnesium stearate, and tabletting.
In the above-mentioned technical solution,
the negative hydrogen ions are absorbed into micropores in the oyster calcium powder, and finally the negative hydrogen ion carrier which is stable at normal temperature is generated, namely the negative hydrogen oyster calcium powder. In the low oxygen partial pressure environment in vivo, once meeting water, the water-soluble polymer slowly releases hydrogen, and can mainly play a role in oxidation resistance and health care. This is probably because on the one hand the negative hydrogen ion directly scavenges the reactive oxygen radicals by transferring the two electrons carried by itself to them; on the other hand, through the in vivo metabolic pathway, negative hydrogen ions, hydrogen or the combined action of the negative hydrogen ions and the hydrogen activate multiple endogenous antioxidases such as GSH-PX, SOD and the like of the organism, so that the activity of the antioxidases is improved, and oxygen free radicals are promoted to be reduced.
The effective components of Ganoderma lucidum extract can accelerate the scavenging of free radicals, and the effect of the extract is not to directly inhibit the generation of free radicals in tissues, but to enhance the activity of peroxidase and accelerate the scavenging of free radicals, thereby achieving the effect of inhibiting aging.
The lycium ruthenicum extract contains rich lycium ruthenicum polysaccharide, carotene, vitamin E, selenium, flavonoid and other antioxidant substances, has a good antioxidant effect on organisms, can resist redundant free radicals of the organisms, and can relieve peroxidation damage of the free radicals so as to play a role in inhibiting aging.
The oyster meat extract contains a large amount of glutamic acid, cysteine, taurine and other effective amino acid components, which are precursors of GSH and can promote biosynthesis of GSH and glutathione-S-transferase (GST) in vivo. Taurine is also an important raw material of sulfur atom, and the sulfur atom is an important antioxidant and has the function of scavenging free radicals and active oxygen. The effective polypeptide components act on target organs and stimulate GSH metabolism. While an increase in the levels of GSH and its related enzymes may promote detoxification and increase chemoprotective capabilities.
Magnesium stearate has lubricating effect in vivo, and can improve digestive ability of intestine and stomach.
In conclusion, the beneficial effects of the invention are as follows:
the negative hydrogen material composition has the health care functions of resisting oxidation and inhibiting aging through animal experiment evaluation.
Detailed Description
The present invention is described in detail below with reference to specific examples, but the use and purpose of these exemplary embodiments are merely to exemplify the present invention, and do not set forth any limitation on the actual scope of the present invention in any form, and the scope of the present invention is not limited thereto.
Example 1
The negative hydrogen material composition of the embodiment is prepared from the following raw materials in parts by weight:
wherein the oyster meat extract is prepared by the following method: grinding fresh oyster meat into slurry, decocting the slurry in pure water for 2-3 times (each time for 1-2 hr), mixing decoctions, concentrating under reduced pressure, and lyophilizing to obtain oyster meat extract.
The ganoderma lucidum extract is prepared by the following method: pulverizing Ganoderma lucidum, adding 60% ethanol solution, extracting at room temperature for 3 times, each time the weight ratio of the material liquid is 1-6, each time 1-2 hr, concentrating the extract, loading onto macroporous resin column, eluting with water, eluting with 30% ethanol, collecting eluate, concentrating, and drying.
The hydrogen-negative oyster calcium powder is prepared by treating oyster shell powder with particle size of 200-300 meshes at 700 deg.C under nitrogen protection; and (3) treating the treated oyster shell powder at the temperature of 1000 ℃ under the protection of mixed gas of hydrogen and nitrogen to obtain the negative hydrogen oyster calcium powder.
The preparation method of the negative hydrogen material composition comprises the following steps:
mixing Carnis Ostreae extract, ganoderma extract, concha Ostreae calcium powder and starch, granulating, adding magnesium stearate, and tabletting.
Example 2
Referring to example 1, unlike example 1, the negative hydrogen material composition of this example is prepared from the following raw materials in parts by weight:
example 3
Referring to example 1, unlike example 1, the negative hydrogen material composition of this example is prepared from the following raw materials in parts by weight:
test of
The hydrogen-negative material composition of example 2 was used as an experimental group for animal experiments.
1 materials and methods
1.1 Experimental animals: male mice of SPF-grade Kunming species, supplied by sbefu (Beijing) Biotechnology Ltd, 20 mice, animal quality certification No.: 110324210100890883 weight 12-14g, production license number: SCXK (Jing) 2019-0010.
1.2 test grouping and dose design: 18 male mice which are adaptive to 6 days and have the weight of 18-22g are selected and randomly divided into an experimental group, a blank control group and a model control group, and the total number of the three groups is 6.
1.3 dose and model building: all the groups are put into the stomach by the approach of gavage. The intragastric volume is 0.2 ml/d after 30d intragastric administration. The control group and the model group are subjected to normal saline intragastric administration, wherein the experimental group prepares the negative hydrogen material composition into 1mg/ml solution by distilled water, and the solution is mixed uniformly and administered for intragastric administration (the solution is used at present). 1h after the gavage every day, D-galactose is prepared into a 10mg/ml solution by a model group and an experimental group by distilled water, and a mouse aging model is established by intraperitoneal injection of 0.2 ml.
1.4 sampling and data determination: mice were dissected 30d after gavage. Taking whole blood of a mouse by an eyeball picking method, putting the whole blood into a 5ml centrifuge tube, standing for 2 hours, then putting the whole blood into a high-speed centrifuge for 3 min at a speed of 2500 r/min, taking supernatant, repeating the operation once again, taking the supernatant to obtain serum, and putting the serum into the centrifuge tube for later use. The brain and liver of the mouse are taken and placed in physiological water, residual blood on the surface is cleaned, and the mouse is placed in a freezing tube and stored in liquid nitrogen. SOD, MDA, T-AOC, GSH-PX, na + -K + The ATPases were determined by the Coomassie Brilliant blue method, using the corresponding kit instructions. Wherein the SOD is superoxide dismutase; MDA is malondialdehyde; GSH-PX is glutathione peroxidase, T-AOC is total antioxidant capacity, na + -K + ATPase is a Na + K + -ATPase.
1.5 statistics of test data: SPSS26 software is used for carrying out the homogeneity of variance test on each test original data to meet the 'homogeneity of variance', and the required data information is statistically processed by a single-factor variance analysis method and a pairwise comparison method of the mean values between a plurality of test groups and a comparison group: and (3) carrying out proper variable conversion on data with non-normal distribution or uneven variance, carrying out statistical treatment after the requirements of normal distribution and uniform variance are met, and adopting non-parametric test if the conditions are not met.
2 results of the test
2.1 Effect of Hydrogen-negative Material composition on mouse serum
Compared with the control group, the injection of D _ galactose can obviously reduce the activity of serum and SOD and obviously improve the MDA content of the serum (P < AOC, SOD activity and GSH-PX activity extremely obviously reduce the MDA content of the serum (P <0.05, P < -0.01). See Table 1.
TABLE 1 Effect of Hydrogen-negative Material composition on mouse serum
| Group of | SOD(U/ml) | MDA(nmol/ml) | GSH-PX(U/ml) | T-AOC(U/ml) |
| Control group | 153.24±7.2 | 3.13±0.45 | 257.22±34.2 | 11.11±1.98 |
| Model set | 117.26±3.1 | 4.21±0.38 | 238.28±28.3 | 7.39±1.67 |
| Experimental group | 138.22±2.3 | 2.27±0.78 | 365.35±47.7 | 11.34±1.86 |
2.2 Effect of Hydrogen-negative Material composition on mouse brain tissue
Compared with control group, the injection of D-galactose can significantly reduce brain tissue SOD activity and GSH-PX activity, and significantly increase brain tissue MDA content (P)<0.05,P<0.01). Compared with a model group, the negative hydrogen material composition can obviously improve the total oxidation resistance and Na of brain tissues + -K + -ATPase activity (P < 0.05) and GSH-PX activity, significantly reduces brain tissue MDA content (P <0.05<0.01). See table 2.
TABLE 2 Effect of negative hydrogen material composition on mouse brain tissue
| Group of | SOD(U/mg) | MDA(nmol/mg) | GSH-PX(U/mg) | T-AOC(U/mg) | Na + -K + -ATPase(U/mg) |
| Control group | 61.84±4.6 | 4.78±0.43 | 15.33±1.38 | 0.36±0.07 | 13.33±0.17 |
| Model set | 49.19±5.7 | 5.76±0.65 | 11.08±0.73 | 0.34±0.04 | 12.76±0.63 |
| Experimental group | 54.36±3.4 | 4.65±0.77 | 14.88±0.92 | 0.43±0.03 | 14.25±0.42 |
2.3 Effect of Hydrogen-negative Material composition on mouse liver tissue
Compared with control group, the injection of D-galactose can significantly reduce liver tissue T-AOC, SOD activity, GSH-PX activity and Na + -K + ATPase (P < 0.05). Compared with a model group, the negative hydrogen material composition can obviously reduce the activity of T-AOC, SOD and GSH-PX of the liver tissue, obviously reduce MDA (P is less than 0.05, P is less than the total weight of the liver tissue and the liver tissue<0.01). See table 3.
TABLE 3 Effect of negative hydrogen material composition on mouse liver tissue
As can be seen from tables 1 to 3, the negative hydrogen material composition has the health-care functions of resisting oxidation and inhibiting aging through animal experiment evaluation.
The above-listed detailed description is only a specific description of a possible embodiment of the present invention, and they are not intended to limit the scope of the present invention, and equivalent embodiments or modifications made without departing from the technical spirit of the present invention should be included in the scope of the present invention.
Claims (7)
1. The negative hydrogen material composition is characterized by being prepared from the following raw materials in parts by weight:
2. the hydrogen-negative material composition according to claim 1, characterized by being prepared from the following raw materials in parts by weight:
3. the hydrogen-negative material composition according to claim 1, wherein the oyster meat extract is prepared by the following method: grinding fresh oyster meat into slurry, decocting the slurry in pure water for 2-3 times (each time for 1-2 hr), mixing decoctions, concentrating under reduced pressure, and lyophilizing to obtain oyster meat extract.
4. The hydrogen-negative material composition according to claim 1, wherein the Ganoderma lucidum extract is prepared by the following method: weighing Ganoderma lucidum, pulverizing, extracting with 75% volume ethanol under reflux for 1-2 hr according to the mass ratio of the material liquid of 1-6, and centrifuging at 2000rpm for 10min to obtain supernatant as extractive solution; performing silica gel column chromatography on the extract, eluting with chloroform-methanol mixed solution with volume ratio of 4.
5. The hydrogen-negative material composition of claim 1, wherein the lycium ruthenicum extract is prepared by: grinding fresh lycium ruthenicum, adding deionized water, soaking for 30 minutes, boiling for 30 minutes, and filtering; decocting the filtrate in water for 30min, filtering, and concentrating the second filtrate under reduced pressure to 2-3g/mL to obtain Lycium ruthenicum Murr extract.
6. The negative hydrogen material composition according to claim 1, wherein the negative hydrogen oyster calcium powder is prepared by treating oyster shell powder having a particle size of 200-300 mesh at 700 ℃ under nitrogen protection; and (3) treating the treated oyster shell powder at the temperature of 1000 ℃ under the protection of a mixed gas of hydrogen and nitrogen to obtain the negative hydrogen oyster calcium powder.
7. A method for preparing the hydrogen-negative material composition according to any one of claims 1 to 6, comprising the steps of:
mixing Carnis Ostreae extract, ganoderma extract, fructus Lycii extract, concha Ostreae calcium powder and starch, granulating, adding magnesium stearate, and tabletting.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211418618.0A CN115708846A (en) | 2022-11-14 | 2022-11-14 | Negative hydrogen material composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211418618.0A CN115708846A (en) | 2022-11-14 | 2022-11-14 | Negative hydrogen material composition and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115708846A true CN115708846A (en) | 2023-02-24 |
Family
ID=85233018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211418618.0A Pending CN115708846A (en) | 2022-11-14 | 2022-11-14 | Negative hydrogen material composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115708846A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116671630A (en) * | 2023-06-06 | 2023-09-01 | 日照生命谷生物科技发展股份公司 | Application of calcium oyster hydrogen storage in special medical food, health product and medicine for preventing and treating obesity, insulin resistance and fatty liver |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106581166A (en) * | 2016-12-14 | 2017-04-26 | 四川岚晟生物科技有限公司 | Anti-fatigue food, health product or pharmaceutical composition |
| CN113057918A (en) * | 2021-03-23 | 2021-07-02 | 日照生命谷生物科技发展股份公司 | Negative hydrogen ion anti-oxidation mask and preparation method thereof |
-
2022
- 2022-11-14 CN CN202211418618.0A patent/CN115708846A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106581166A (en) * | 2016-12-14 | 2017-04-26 | 四川岚晟生物科技有限公司 | Anti-fatigue food, health product or pharmaceutical composition |
| CN113057918A (en) * | 2021-03-23 | 2021-07-02 | 日照生命谷生物科技发展股份公司 | Negative hydrogen ion anti-oxidation mask and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116671630A (en) * | 2023-06-06 | 2023-09-01 | 日照生命谷生物科技发展股份公司 | Application of calcium oyster hydrogen storage in special medical food, health product and medicine for preventing and treating obesity, insulin resistance and fatty liver |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Qiao et al. | Antioxidant activities of polysaccharides from Hyriopsis cumingii | |
| KR100813914B1 (en) | The conversion and modification of natural medicines by intestinal probiotics co-fermentation cultures | |
| CN115708846A (en) | Negative hydrogen material composition and preparation method thereof | |
| CN115708838A (en) | Oyster negative hydrogen tablet and preparation method thereof | |
| CN113521115B (en) | Aflatoxin detoxification composition and preparation method and application thereof | |
| CN101514318A (en) | Tibetan pharmaceutical health care wine | |
| Ik Lee et al. | Ginsenoside‐Free Molecules from Steam‐Dried Ginseng Berry Promote Ethanol Metabolism: An Alternative Choice for an Alcohol Hangover | |
| US20140011244A1 (en) | Method for Producing Probiotically Derived Compounds | |
| CN104940241B (en) | A kind of selenium worm grass compound preparation of prevention climacteric metancholia of women | |
| Vamanu et al. | Therapeutic potential of functional product based on wild edible mushrooms | |
| CN100493510C (en) | Application of compound 6-furfuryl amino purine in preparing medicine for treating myocardial tissue oxidizing damage | |
| CN106955290A (en) | It is a kind of to treat composition of degenerative disorders and application thereof | |
| CN113615833A (en) | Mitochondrial nutrient composition for improving cardiovascular disease and application thereof | |
| CN110235990A (en) | It is a kind of to adjust pigeon racing and circle in the air the composition of physical efficiency | |
| AU2021105462A4 (en) | Use of fructus corni nano-powder in resisting type 2 diabetes mellitus | |
| KR101049086B1 (en) | Composition comprising the ginjum mugwort fermentation broth as an active ingredient, a method of manufacturing the same, and health food, a therapeutic agent and supplementary feed for horse-motor disease, animal cataracts, dog PARAJO treatment and a method of treating the same. | |
| Ghanim et al. | Effects of two different doses of vitamin B2 and a single dose of vitamin B12 against cyclophosphamide induced nephrotoxicity | |
| Esan et al. | The Effects of okra (Abelmoschus esculentus (L) M oench) fruit extracts on diabetes markers in streptozotocin-induced diabetic rats. Arch | |
| Lopes et al. | Bioavailability of Li-enriched mushrooms and protection against oxidative stress in pigs: First study in vivo | |
| Kuo et al. | Dietary administration of mangosteen, Garcinia mangostana, peel extract enhances the growth, and physiological and immunoendocrinological regulation of prawn, Macrobrachium rosenbergii | |
| Ominyi et al. | Ameliorative effects of aqueous seed-extract of Dacryodes edulis on doxorubicin-induced cardiac tissue damage in albino rats | |
| CN111789241A (en) | Medicinal and edible composition with function of scavenging free radicals of human body and preparation method thereof | |
| CN1954835A (en) | Sea-buckthorn plant preparation and its preparation method | |
| CN115368405A (en) | Preparation method and biological application of cerium phytate complex | |
| CN116531465A (en) | Chinese medicinal prescription for treating tumor and/or pulmonary nodule and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |